PMID- 37483239 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230725 IS - 2470-1343 (Electronic) IS - 2470-1343 (Linking) VI - 8 IP - 28 DP - 2023 Jul 18 TI - Imine-Linked Covalent Organic Frameworks: A Biocompatible and pH-Dependent Carrier for In Vitro Sustained Release of Doxorubicin. PG - 25565-25573 LID - 10.1021/acsomega.3c03316 [doi] AB - Among the novel drug delivery systems (DDSs), covalent organic frameworks (COFs) show promising features in pharmaceutical science. In this paper, an imine-linked COF with hexagonal topology was synthesized using the autoclave condition. Then, the prepared COF (APB-COF) was used as a pH-dependent carrier for in vitro release of doxorubicin (DOX). The intrinsic properties of APB-COF caused reaching an excellent drug encapsulation efficiency. DOX@APB-COF shows an exemplary pH-dependent release in two different pHs. DOX release at pH = 7.4 was 32%, which increased to 54% by changing the pH to the cancer cell pH (pH = 5.4). Moreover, the cytotoxicity of APB-COF and DOX@APB-COF was studied using the standard MTT test against MCF10 (normal breast cell line) and MDAmb231 cells (breast cancer cell line), respectively. It was observed that the APB-COF does not affect cell proliferation, whereas the DOX@APB-COF only limits cancer cell proliferation. Using APB-COF as the drug carrier can pave the way for using COFs in innovative DDSs. CI - (c) 2023 The Authors. Published by American Chemical Society. FAU - Mokhtari, Nazanin AU - Mokhtari N AD - Department of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Islamic Republic of Iran. FAU - Dinari, Mohammad AU - Dinari M AUID- ORCID: 0000-0001-5291-7142 AD - Department of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Islamic Republic of Iran. FAU - Khosravi Esmaeiltarkhani, Fatemeh AU - Khosravi Esmaeiltarkhani F AD - Department of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Islamic Republic of Iran. LA - eng PT - Journal Article DEP - 20230703 PL - United States TA - ACS Omega JT - ACS omega JID - 101691658 PMC - PMC10357574 COIS- The authors declare no competing financial interest. EDAT- 2023/07/24 06:42 MHDA- 2023/07/24 06:43 PMCR- 2023/07/03 CRDT- 2023/07/24 04:26 PHST- 2023/05/12 00:00 [received] PHST- 2023/06/21 00:00 [accepted] PHST- 2023/07/24 06:43 [medline] PHST- 2023/07/24 06:42 [pubmed] PHST- 2023/07/24 04:26 [entrez] PHST- 2023/07/03 00:00 [pmc-release] AID - 10.1021/acsomega.3c03316 [doi] PST - epublish SO - ACS Omega. 2023 Jul 3;8(28):25565-25573. doi: 10.1021/acsomega.3c03316. eCollection 2023 Jul 18.